$NKTR Company News AstraZeneca's NDA for

New Post Public Reply Private Reply Replies (0) Message Board

Feb 4, 2014 at 9:38 AM

$NKTR Company News

AstraZeneca's NDA for Naloxegol accepted
3:35 a.m. Nov. 19, 2013
- MarketWatch.com

Nektar Therapeutics shares soar on earnings, new drug prospects

12:31 p.m. Nov. 8, 2013
- Russ Britt

Rough market day for Nektar, while Pharmacyclics and Regeneron soar

5:21 p.m. Sept. 26, 2013
- Russ Britt

Nike shares swoosh higher after earnings
4:53 p.m. Sept. 26, 2013
- Wallace Witkowski

Nektar shares drop 25% after study misses endpoint
3:45 p.m. Sept. 26, 2013
- Wallace Witkowski

FDA grants fast-track status for Nektar drug
10:43 a.m. Nov. 7, 2012
- MarketWatch.com

S&P 500 clears trendline resistance
10:01 a.m. July 30, 2012
- Michael Ashbaugh

Charting the latest tape bomb
10:02 a.m. July 23, 2012
- Michael Ashbaugh

Wednesday’s biggest gaining & declining stocks
5:04 p.m. Feb. 29, 2012
- Kate Gibson

Nektar sells royalties for two drugs
11:31 a.m. Feb. 29, 2012
- MarketWatch.com

S&P 500 vacillates at the March peak
9:47 a.m. April 4, 2011
- Michael Ashbaugh

Wednesday’s biggest gaining and declining stocks
4:24 p.m. Jan. 19, 2011
- Kate Gibson

Monday’s biggest gaining and declining stocks
4:24 p.m. Dec. 13, 2010
- Kate Gibson

Drug indexes hug the flat line
10:57 a.m. Dec. 13, 2010
- Val Brickates Kennedy

Wednesday's biggest gaining and declining stocks
4:40 p.m. March 3, 2010
- MarketWatch

Nasdaq hesitates at the 50-day moving average
9:46 a.m. Feb. 18, 2010
- Michael Ashbaugh

S&P 500 settling into the 2004 trading range?
11:38 a.m. Feb. 1, 2010
- Michael Ashbaugh

S&P pulls in from the 1,100 mark
9:15 a.m. Oct. 16, 2009
- Michael Ashbaugh

U.S. benchmarks survive initial test of the 50-day
9:19 a.m. Oct. 5, 2009
- Michael Ashbaugh

Miners, banks weigh on U.K. market
11:07 a.m. Sept. 21, 2009
- Simon Kennedy

Russell 2000 Rebalance May Bring Huge Buying in Key Stocks
8:29 a.m. Jan. 31, 2014
- 247WallSt.com

Nektar Therapeutics (NKTR) Looks Good: Stock Up 6.8% in Session - Tale of the Tape

8:44 a.m. Jan. 24, 2014
- Zacks.com

Nektar Therapeutics (NKTR) Is Today's Pre-Market Mover With Heavy Volume Stock

8:27 a.m. Jan. 23, 2014
- TheStreet.com

SA PRO: Top Long And Short Ideas, Wednesday January 22

7:30 a.m. Jan. 23, 2014
- Seeking Alpha

Nektar Therapeutics Prices 8.5M Share Offering at $12.75/Share

9:50 p.m. Jan. 22, 2014
- benzinga.com

Cowen names its top biotech stocks with biggest upside to buy in 2014

6:45 p.m. Jan. 22, 2014
- Seeking Alpha

Interesting NKTR Put And Call Options For March 22nd

11:56 a.m. Jan. 22, 2014
- TheStreet.com

Nektar Momentum Continues To Grow

11:52 a.m. Jan. 22, 2014
- Seeking Alpha

Cowen Top Biotech Stocks to Buy for 2014 With Huge Upside
8:54 a.m. Jan. 22, 2014
- 247WallSt.com

Nektar Therapeutics Announces Public Offering of 8.5M Shares of Common Stock

3:14 p.m. Jan. 21, 2014
- benzinga.com

Nektar Therapeutics Is The Seattle Genetics Of San Francisco But It Could Be More

1:29 p.m. Jan. 21, 2014
- Seeking Alpha

Nektar Presents Positive Data from Phase 1 Study of Etirinotecan Pegol in Combination with 5-Flourouracil/Leucovorin at 2014 Gastrointestinal Cancers Symposium

11:34 a.m. Jan. 18, 2014
- benzinga.com

Pipeline Progress at Nektar - Analyst Blog

5:20 p.m. Jan. 16, 2014
- Zacks.com

Piper Jaffray Has Four Biotech Stocks to Buy With Huge Potential
7:20 a.m. Jan. 16, 2014
- 247WallSt.com

Nektar Therapeutics' CEO Presents at 32nd Annual JPMorgan Healthcare Conference (Transcript)

4:05 p.m. Jan. 14, 2014
- Seeking Alpha

Cadence Pharmaceuticals Inc. (CADX) Soars: Stock Adds 13.0% in Session - Tale of the Tape

9:21 a.m. Jan. 14, 2014
- Zacks.com

Time to Buy Nektar Therapeutics (NKTR) After Recent Moving Average Crossover? - Tale of the Tape

7:21 a.m. Jan. 14, 2014
- Zacks.com

Etirinotecan Pegol Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer

7:18 a.m. Jan. 14, 2014
- benzinga.com

Flamel Technologies (FLML) in Focus: Stock Jumps 8.6% - Tale of the Tape

8:37 a.m. Jan. 13, 2014
- Zacks.com

Scorching Hot Biotech Tape: Small-Cap and Mid-Cap Stocks on Fire
8:33 a.m. Jan. 10, 2014
- 247WallSt.com

Nektar Therapeutics Prices Public Offering of Common Stock
9:59 p.m. Jan. 22, 2014
- PR Newswire - PRF

Nektar Therapeutics Announces Public Offering of 8,500,000 Shares of Common Stock
4:10 p.m. Jan. 21, 2014
- PR Newswire - PRF

Nektar Presents Positive Clinical Data from a Phase 1 Study of Etirinotecan Pegol (NKTR-102) in Combination with 5-Flourouracil/Leucovorin at the 2014 Gastrointestinal Cancers Symposium
12:00 p.m. Jan. 18, 2014
- PR Newswire - PRF

Market Technicals Simplified: Inovio Pharma, Sequenom, Nektar Therapeutics, and Discovery Laboratories
7:33 a.m. Jan. 16, 2014
- PR Newswire - PRF

Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer
8:15 a.m. Jan. 14, 2014
- PR Newswire - PRF

First Subjects Dosed in Phase 1 Clinical Study of NKTR-171, A New Peripherally-Restricted Sodium Channel Blocker to Treat Neuropathic Pain
8:00 a.m. Jan. 14, 2014
- PR Newswire - PRF

Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
5:38 p.m. Jan. 8, 2014
- PR Newswire

Addition to Indices, and Stock Price Movements - Research Report on ACADIA Pharmaceuticals, InterMune, Tandem Diabetes Care, Nektar Therapeutics and Greatbatch
8:00 a.m. Dec. 25, 2013
- PR Newswire

AAAResearchReports.com Pre-Market Technical Analysis: Inovio Pharma, Sequenom, Nektar Therapeutics, and Discovery Laboratories
8:23 a.m. Dec. 17, 2013
- PR Newswire

New Research Arrangements, Investor Conference Schedules, Reimbursement Agreements, and NDA Acceptances - Research Report on Quintiles, Insys, HeartWare, Given Imaging, and Nektar
8:00 a.m. Nov. 28, 2013
- PR Newswire

Financing, Special Reports, and Clinical Trial Updates - Research Report on PDL, DexCom, Quintiles, KYTHERA, and Nektar
8:00 a.m. Nov. 20, 2013
- PR Newswire

Morning Research: Inovio Pharma Inc., Sequenom Inc., Nektar Therapeutics, and Discovery Laboratories Inc.
9:03 a.m. Nov. 19, 2013
- PR Newswire

New Drug Application For Naloxegol Accepted By United States Food And Drug Administration
7:00 a.m. Nov. 19, 2013
- PR Newswire

Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A
9:34 a.m. Nov. 13, 2013
- PR Newswire

Baxter Completes Enrollment in Phase III Clinical Trial of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A
9:00 a.m. Nov. 13, 2013
- BusinessWire

Updates on Clinical Studies and Milestone Revenues - Research Report on Cyberonics, West, Nektar, OraSure, and Akorn
8:00 a.m. Nov. 12, 2013
- PR Newswire

Critical Alerts For Salix Pharmaceuticals, Endo Pharmaceuticals, Nektar Therapeutics, Riverbed Technology, and Ubiquiti Networks Released By InvestorsObserver
9:31 a.m. Nov. 11, 2013
- PR Newswire

Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4:15 p.m. Nov. 7, 2013
- PR Newswire

Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
4:00 p.m. Oct. 30, 2013
- PR Newswire

Today's Research: Inovio Pharmaceuticals Inc., Sequenom Inc., Nektar Therapeutics, and Discovery Laboratories Inc.
8:00 a.m. Oct. 28, 2013
- PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

HelloNation Brings 'Edvertising' to NC REALTORS® Event

HelloNation's Bold Step into Real Estate Networking October 8th to the 11th is shaping up to be a pivotal few days in Wilmington, North Carolina. Here’s the scoop: HelloNation, known for its innovative 'edvertising' model, is joining the bustling crowd at the 2026 NC REALTORS® Convention. This isn’t just any get-together—it's the grandest annual jamboree for real...

Ornellaia's 2026 Harvest: Adapting to Nature's Whims

A Year Marked by Weather's Unpredictable Dance Nobody said making wine was a walk in the park, and the folks at Ornellaia know better than most how to roll with whatever nature throws their way. The 2026 harvest story is as much about unlocking the secrets of the soil as it is about navigating the quirks of the weather. Situated in Bolgheri, Italy, this year's vintage...

Vitamin Angels Drives Global Nutrition Advancements

Navigating the Waters of Global Nutrition Bet you never thought a vitamin program could spearhead the front lines of healthcare, huh? Vitamin Angels are grinding away under the radar, shifting the landscape for maternal and child nutrition. At the heart of it all is their vision to make UNIMMAP multiple micronutrient supplementation (MMS) a staple in the global playbook....

C3EL Expands Federal Footprint with Strategic Contracts

Pushing Boundaries in Federal Contracts What a ride C3EL's had in Government Fiscal Year 2026! Let me tell you, they’ve bagged a bunch of contracts that’d make any company’s mouth water. Kicking things off, they snagged a prime cybersecurity contract from the U.S. Air Force. Considering our current cybersecurity landscape, that's like striking gold. But they...

Merit Expands in New York with Bold Acquisition Move

Merit Financial's Growth Trajectory Takes a Leap You watch the movers and shakers in this game long enough, and you start to see patterns. Merit Financial Advisors is one of those juggernauts you'd better keep an eye on. These folks just scooped up Moldenhauer & Associates—a firm that's been a staple in Orchard Park, New York—for a cool $1.1 billion worth of client...

Wally Disrupts Dental Industry with $25M Funding

A New Breath of Fresh Air for Dental Care Dental visits—a tedious, costly affair we've all dreaded. So, when Wally rolls out an overhaul in this stale landscape, it's worth taking notice. With $25 million in their pockets from Series A funding led by Maveron, Wally's swaggering in with a plan to flip the script on dental care across the nation. Redefining the Dental...

Duke Energy's Cost-Protection Plan Shields Ratepayers

Shielding Customers From Data Center Costs Let's get right into the thick of it: Duke Energy's latest move is a strategic one, shrouded in industry terms but with a real impact on regular folks' wallets. The company's agreement with heavyweights like Amazon, Google, and Meta aims to protect existing customers in North Carolina from getting hit with the costs of powering...

Decoding CarBravo-Certified vs Traditional Used Cars

What’s Behind Door Number One: CarBravo Certification When you walk onto a car lot these days, it's a mixed bag: shiny badges boasting certifications or basic used car signage. For anyone who's spent time around cars, two types stick out—there’s your CarBravo-certified vehicles and your good ol' used cars. Now, Marissa McCoy and Jill Maniaci from Heidebreicht...

EMCO's New Automated Facility Could Shake Industry

A Novel Leap in Production Capacity EMCO Industries just put a solid foot on the accelerator with their brand-new, shiny, fully automated plant over in Claremore, Oklahoma. If you're glancing at heavy-duty trailer springs, you can't ignore the fact that this is a multimillion-dollar investment. Heck, this monstrous 30,000-square-foot facility more than doubles what EMCO...

U. of Phoenix and LACCD Launch 3+1 Degree Pathway

Opening the Floodgates for Ambitious Community College Students When it comes to climbing the educational ladder, not everyone starts at the same rung. That's a fact we've all come to terms with in one way or another. Enter the University of Phoenix and the Los Angeles Community College District with a solution to expand educational access. The 3+1 Program: A Cost-Saving...